Search

Your search keyword '"Cornette, J M J"' showing total 2 results
Start Over Author "Cornette, J M J" Database Academic Search Index
2 results on '"Cornette, J M J"'

1. Methods and considerations concerning cardiac output measurement in pregnant women: recommendations of the International Working Group on Maternal Hemodynamics.

Author

Bijl, R. C., Valensise, H., Novelli, G. P., Vasapollo, B., Wilkinson, I., Thilaganathan, B., Stöhr, E. J., Lees, C., van der Marel, C. D., Cornette, J. M. J., Cockcroft, J., Cornette, J., Duvekot, J. J., Ferrazzi, E., Foo, F. L., Ghossein‐Doha, C., Gyselaers, W., Khalil, A., McEniery, C. M., and Meah, V.

Subjects
*CARDIAC output, *PREGNANT women, *HEMODYNAMICS, *VASCULAR resistance, *TEAMS in the workplace, *STROKE volume (Cardiac output)
Abstract

Cardiac output (CO), along with blood pressure and vascular resistance, is one of the most important parameters of maternal hemodynamic function. Substantial changes in CO occur in normal pregnancy and in most obstetric complications. With the development of several non-invasive techniques for the measurement of CO, there is a growing interest in the determination of this parameter in pregnancy. These techniques were initially developed for use in critical-care settings and were subsequently adopted in obstetrics, often without appropriate validation for use in pregnancy. In this article, methods and devices for the measurement of CO are described and compared, and recommendations are formulated for their use in pregnancy, with the aim of standardizing the assessment of CO and peripheral vascular resistance in clinical practice and research studies on maternal hemodynamics. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

2. Cost-effectiveness of diagnostic testing strategies including cervical-length measurement and fibronectin testing in women with symptoms of preterm labor.

Author

van Baaren, G.‐J., Vis, J. Y., Wilms, F. F., Oudijk, M. A., Kwee, A., Porath, M. M., Scheepers, H. C. J., Spaanderman, M. E. A., Bloemenkamp, K. W. M., Haak, M. C., Bax, C. J., Cornette, J. M. J., Duvekot, J. J., Nij Bijvanck, B. W. A., van Eyck, J., Franssen, M. T. M., Sollie, K. M., Vandenbussche, F. P. H. A., Woiski, M., and Bolte, A. C.

Subjects
*FIBRONECTINS, *BLOOD proteins, *PREMATURE labor, *EXTRACELLULAR matrix proteins, *LABOR complications (Obstetrics), *CERVIX uteri, *COMPARATIVE studies, *COST effectiveness, *FETAL ultrasonic imaging, *GESTATIONAL age, *HOSPITAL care, *LONGITUDINAL method, *RESEARCH methodology, *MEDICAL cooperation, *RESEARCH, *EVALUATION research, *PREDICTIVE tests, *DIAGNOSIS, *ECONOMICS
Abstract

Objective: To evaluate the cost-effectiveness of combining cervical-length (CL) measurement and fetal fibronectin (fFN) testing in women with symptoms of preterm labor between 24 and 34 weeks' gestation.Methods: This was a model-based cost-effectiveness analysis evaluating seven test-treatment strategies based on CL measurement and/or fFN testing in women with symptoms of preterm labor from a societal perspective, in which neonatal outcomes and costs were weighted. Estimates of disease prevalence, test accuracy and costs were based on two recently performed nationwide cohort studies in The Netherlands.Results: Strategies using fFN testing and CL measurement separately to predict preterm delivery are associated with higher costs and incidence of adverse neonatal outcomes compared with strategies that combine both tests. Additional fFN testing when CL is 15-30 mm was considered cost effective, leading to a cost saving of €3919 per woman when compared with a treat-all strategy, with a small deterioration in neonatal health outcomes, namely one additional perinatal death and 21 adverse outcomes per 10 000 women with signs of preterm labor (incremental cost-effectiveness ratios €39 million and €1.9 million, respectively). Implementing this strategy in The Netherlands, a country with about 180 000 deliveries annually, could lead to an annual cost saving of between €2.4 million and €7.6 million, with only a small deterioration in neonatal health outcomes.Conclusion: In women with symptoms of preterm labor at 24-34 weeks' gestation, performing additional fFN testing when CL is between 15 and 30 mm is a viable and cost-saving strategy. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results